Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. announced a significant change in its shareholder structure, as Shanghai Shangshi Yangtze River Delta Ecological Development Co., Ltd. transferred its 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. to Shanghai Shangshi (Group) Co., Ltd. for RMB6,721.5148 million. This transaction results in Shanghai Shangshi (Group) Co., Ltd. holding 100% of Shanghai Pharmaceutical (Group), which is a controlling shareholder of Shanghai Pharmaceuticals Holding Co., Ltd. The change is expected to have implications for the company’s governance and strategic direction, as well as affecting its market positioning and stakeholder relationships.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is a major player in the Chinese market, with a significant shareholding structure that involves various stakeholders.
Average Trading Volume: 4,060,084
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$76.68B
See more data about 2607 stock on TipRanks’ Stock Analysis page.